Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen hopes European Xeplion launch will elbow Zyprexa aside

This article was originally published in Scrip

Executive Summary

The European Commission has given marketing authorisation to Janssen-Cilag's once-a-month injectable antipsychotic Xeplion (paliperidone palmitate) for the treatment of schizophrenia, but the drug is unlikely to be marketed anywhere in Europe much before the autumn of this year. A company spokesperson told Scrip that it would be at least a year or even 18 months before the product is rolled out across the European Union. The company was unable to comment in detail on a timetable for either reimbursement discussion or outline a marketing strategy.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC012156

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel